The Promise and Limits of Trump's Psychedelic Therapy Order
The article adopts a measured libertarian perspective that acknowledges both the benefits of Trump's order and concerns about access equity. Language is balanced—'promise and limits' frames a genuine tension rather than condemning or celebrating the policy. The focus on regulatory facilitation and who benefits reflects typical Reason framing that questions government gatekeeping while maintaining analytical distance.
Primary voices: elected official, state or recognized government
- This article does not address potential safety concerns or adverse event data from psychedelic trials
- This article does not examine pharmaceutical industry positioning or profit incentives in psychedelic drug development
- This article does not discuss equity-based critiques of access restricted to those who can navigate FDA approval pathways
Framing may shift depending on whether FDA expedites approvals and whether access disparities materialize or are addressed through subsequent policy.
Reform-orientedBoth-sides framingOpinion/analysis
The president's facilitation of research and FDA review could help make psychedelics available to approved patients. But what about everyone else?
Full article not available — click below to read at the source.
Comments
No comments yet. Be the first.
Sign in to leave a comment.